ChronoScale Corporation (Ticker: CHRN) is a cutting-edge biotechnology company dedicated to transforming healthcare by developing and commercializing innovative therapeutics that address unmet medical needs. The firm boasts a robust pipeline supported by strategic collaborations and is committed to leveraging advanced technologies to enhance patient care outcomes. Through its unwavering focus on scientific excellence and a dynamic approach to the evolving healthcare landscape, CHRN is strategically positioned to emerge as a prominent leader in the biotechnology sector, poised to capitalize on new opportunities within the industry.
| Revenue (TTM) | $71.60M |
| Gross Profit (TTM) | $-17.09M |
| EBITDA | $26.58M |
| Operating Margin | -47.10% |
| Return on Equity | -38.50% |
| Return on Assets | -6.70% |
| Revenue/Share (TTM) | $0.52 |
| Book Value | $1.24 |
| Price-to-Book | 16.70 |
| Price-to-Sales (TTM) | 30.67 |
| EV/Revenue | 43.53 |
| EV/EBITDA | 151.13 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1.90% |
| Shares Outstanding | $145.64M |
| Float | $4.11M |
| % Insiders | 99.89% |
| % Institutions | 1.46% |
Volatility is currently expanding
MENLO PARK, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- ChronoScale Holdings Corporation (NASDAQ: CHRN) (“ChronoScale” or the “Company”), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, reported financial results for the fiscal first quarter ended August 31, 2026.
Expanded agreement with an existing AI infrastructure customer and new customer agreement increases contracted deployment pipeline and is expected to drive Company annualized revenue run rate to $1 billion by calendar Q3 2027 ChronoScale completes previously disclosed sale of Ekso Bionics business unit MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- ChronoScale Holdings Corporation (NASDAQ: CHRN) (“ChronoScale” or the “Company”), an accelerated compute platform purpose-built to support demanding artificial intelligence (AI) workloads, today announced a significant expansion of an existing customer agreement and a separate agreement with a new customer, that increases the scale of its contracted AI infrastructure deployments and further strengthens the Company's contracted revenues.
MENLO PARK, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ: CHRN), (“ChronoScale” or the “Company”), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced plans with Microsoft for a 50-megawatt (MW) AI compute deployment in North America.
Nutanix and ChronoScale plan to integrate their platforms so enterprises can extend into ChronoScale GPU-as-a-Service, pre-paid inference tokens through ChronoScale Token Factory, and a locally-deployed ChronoScale Foundry for enterprise agentic AI workflows ChronoScale to leverage Nutanix Agentic AI software solution for neoclouds to deliver broad portfolio of accelerated compute and AI services Collaboration extends to go-to-market, joint solution development, technical integration, and customer engagement programs SAN JOSE, Calif. and Menlo Park, Calif.
DALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- Applied Digital Corporation (Nasdaq: APLD) ("Applied Digital" or the Company"), a U.S.-based designer, developer, owner, and operator of large-scale, purpose-built data centers engineered to support high-performance computing (“HPC”) workloads, including artificial intelligence (“AI”), machine learning, and other accelerated-compute applications, reported financial results for the fiscal fourth quarter ended May 31, 2026. The Company also provided operational updates.
DALLAS, June 04, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ: CHRN) (“ChronoScale” or the “Company”), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointments of Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer. The appointments strengthen ChronoScale's executive leadership team as the Company expands its AI infrastructure platform and accelerates delivery of large-scale compute solutions for enterprises, hyperscalers, and AI innovators worldwide.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CHRN and any ticker you trade — then tracks every position and per-strategy win rate.
